Energy & environment · 19/10/2026

AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease

In a Phase 2a clinical trial, AbbVie's ABBV-466 showed superior results in treating moderate to severe Crohn's disease, achieving higher endoscopic remission rates compared to existing treatments at Week 12, the primary endpoint.